Skip to content
DataLookout
Menu

TRAINNCT07268339

A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Start date changed from estimate of Dec 1, 2025 to Apr 24, 2026
    • Eligibility criteria expanded, about 16 words
    • Study sites: 1 to 2
    • Secondary endpoints: details revised at 4 of 10 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

To compare event-free survival between BCG and radiotherapy with radiosensitisation.
Timeframe: From baseline to at least 96 weeks after initial of treatment.

Secondary (6)

To determine the difference between BCG and radiotherapy in terms of patient-reported symptoms.
To evaluate each component of the primary outcome comparing between BCG and radiotherapy with radiosensitisation.
To establish the tolerability and safety of radiotherapy.
To determine the difference in cancer specific survival between groups.
To determine the difference in treatment fidelity between the groups.
Show 1 moreShow less
To determine the cost-effectiveness of radiotherapy with radiosensitisation compared to BCG.

Arms and interventions

Control Arm: BCGActive comparator

This arm is standard of care for this patient group. A standard protocol of 6 weekly intravesical installations, followed by 3 weekly instillations at approximately 3, 6, 12, 18, 24, 30 months and 36 months (depending on toxicity). Stock is taken and given per local hospital guildlines.

Experimental Arm: Radiotherapy with Radiosentiser drugs.Experimental

Patients randomised to the radiotherapy arm will receive a hypofractionated schedule of external beam radiotherapy with a regimen of 55Gy in 20 fractions given once daily Monday to Friday over 4 weeks. Radiotherapy will be delivered with a conventional or 3D conformal technique with an empty bladder. It will be administered concurrently with a radiosensitiser (detailed below) selected by the treating physician according to local institutional practice. Radiosensitiser will be selected as one option from the following: * Gemcitabine 75-100mg/m2 administered once a week during a four-week radiotherapy course. Cycle 1 will be given on the first radiotherapy day, to a planned total of 4 cycles. 2-4 hours prior to radiotherapy * 5-FU and Mitomycin C - Fluorouracil 500mg/m2 Days 1-5 and 16-20 via continuous infusion. Mitomycin C 12mg/m2 Day 1 via intravenous infusion * Carbogen and nicotinamide (CON) - 2% CO2 and 98% O2 Carbogen will be delivered through a closed breathing system with

Radiation: radiotherapy

Other: BCG

Sites

2 sites in 1 country